Advarra A.I CyberSecurity Scoring
29/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Advarra in 2026.
No incidents recorded for Advarra in 2026.
No incidents recorded for Advarra in 2026.
Pharmaceutical Manufacturing
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Latest updates, reports, and threat intel affecting the global network.
Baylor College of Medicine was informed of a cybersecurity incident involving Advarra, a vendor the College uses to provide clinical research information...
Advarra explains that the incident resulted in an unauthorized party being able to access consumers' sensitive information, which includes their names and...
Ransomware crooks claim they've stolen data from a firm that helps other organizations run medical trials after one of its executives had their cellphone...
A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.
A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.
Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.
SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.
The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.